Medgenics (MDGN) Misses Q1 EPS by 10c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Wall St futures muted as higher oil prices temper risk appetite after S&P record close
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
Medgenics Reports First Quarter 2015 Financial Results
April 17, 2015 8:00 AM EDTCommenced enrollment in mid-dose arm of MDGN-201 study Initiated peritoneal dialysis study in Israel Filed U.S. IND for TARGTEPO renal anemia programs Advanced collaboration activities with CHOP Progressed TARGTCNS program with Harvard University
PHILADELPHIA, April 17, 2015 (GLOBE NEWSWIRE) -- Medgenics, Inc. (NYSE: MDGN) (the Company), the developer of a proprietary platform for the sustained production and delivery of therapeutic proteins and peptides in patients using ex vivo gene therapy and... More
